Year: 2021
Type: article
Abstract: Adjuvant systemic therapies are now routinely used following resection of stage III melanoma, however accurate prognostic information is needed to better stratify patients. We use differential expression analyses of primary tumours from 204 RNA-sequenced melanomas within a large adjuvant trial, identifying a 121 metastasis-associated gene signature. This signature strongly associated with progression-free (HR = 1.63, p = 5.24 × 10 −5 ) and overall survival (HR = 1.61, p = 1.67 × 10 −4 ), was validated in 175 regional lymph nodes metastasis as well as two externally ascertained datasets. The machine learning classification models trained using the signature genes performed significantly better in predicting metastases than models trained with clinical covariates ( p AUROC = 7.03 × 10 −4 ), or published prognostic signatures ( p AUROC < 0.05). The signature score negatively correlated with measures of immune cell infiltration (ρ = −0.75, p < 2.2 × 10 −16 ), with a higher score representing reduced lymphocyte infiltration and a higher 5-year risk of death in stage II melanoma. Our expression signature identifies melanoma patients at higher risk of metastases and warrants further evaluation in adjuvant clinical trials.
Source: Nature Communications
Authors: Manik Garg, Dominique-Laurent Couturier, Jérémie Nsengimana, Nuno A. Fonseca, Matthew Wongchenko, Yibing Yan, Martin Lauss, Göran B. Jönsson, Julia Newton-Bishop, Christine Parkinson, Mark R. Middleton, D. Timothy Bishop, Sarah McDonald, Nikki Stefanos, John Tadross, Ismael A. Vergara, Serigne Lo, Felicity Newell, James S. Wilmott, John F. Thompson, Georgina V. Long, Richard A. Scolyer, Pippa Corrie, David J. Adams, Alvis Brazma, Roy Rabbie
Institutions: European Bioinformatics Institute, University of Cambridge, Cancer Research UK, University of Leeds, Newcastle University, Universidade do Porto, Centro de Investigação em Biodiversidade e Recursos Genéticos, Genentech, Lund University, Cambridge University Hospitals NHS Foundation Trust, University of Oxford, The University of Sydney, Melanoma Institute Australia, Imam Abdulrahman Bin Faisal University, QIMR Berghofer Medical Research Institute, Royal North Shore Hospital, Royal Prince Alfred Hospital, NSW Health Pathology, Wellcome Sanger Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,560
OpenAlex ID: W3123792751
